Annexon, Inc.

What they do

Annexon is advancing a platform of targeted immunotherapies that inhibit the classical complement cascade to treat complement-mediated neuroinflammatory diseases. Its pipeline includes tanruprubart, a single-infusion therapy for GBS; vonaprument, an intravitreal C1q inhibitor for geographic atrophy; and ANX1502, an oral small molecule for autoimmune conditions. The company is focused on clinical development and regulatory approvals; it does not yet have approved products or commercial revenue.

Revenue drivers

• No approved products; no revenue — Annexon is pre-commercial, with zero product sales historically. Its financial position relies on funding from equity offerings and collaborations.
• Tanruprubart (GBS) — Potential first revenue driver if approved; the company has filed an MAA with the EMA and plans a BLA submission to the FDA in 2026, targeting the acute GBS market (~150,000 patients annually).
• Vonaprument (GA) — Late-stage asset in geographic atrophy; completed enrollment in the Phase 3 ARCHER II trial (659 patients) with topline data expected in Q4 2026, targeting a market of >8 million patients worldwide.
• ANX1502 (oral C1s inhibitor) — Early-stage oral small molecule for autoimmune conditions; Phase 1 data supportive of further development, but no near-term commercialization.

Recent performance

For Q2 2026, Annexon reported cash and equivalents of $199.3 million, total assets of $246.1 million, and total liabilities of $60.0 million as of June 30, 2026. Full-year 2025 net loss widened to $206.7 million from $138.2 million in 2024, with diluted EPS of -$1.34 and operating cash flow of -$186.4 million. The company has never paid dividends. These results reflect increased R&D spending ahead of pivotal data readouts.

Strategy

Annexon is prioritizing two late-stage registrational programs: advancing tanruprubart toward first approval in GBS and vonaprument toward pivotal data in geographic atrophy. The company is also developing ANX1502, an oral small molecule for autoimmune conditions. Management is engaging with EU and U.S. regulators to secure marketing approvals, including an ongoing MAA review in Europe and a planned BLA submission for tanruprubart in Q4 2026. For vonaprument, the company expanded the Phase 3 program to add a Month 24 dual primary endpoint and an open-label extension study, and is positioning for global registration. The strategy includes broadening the tanruprubart data package through the open-label FORWARD study to support a broad label and Western patient generalizability.

Risks

• Clinical and regulatory failure — The ARCHER II topline data (due Q4 2026) and regulatory reviews for tanruprubart are binary catalysts; negative results could impair the pipeline.
• Capital depletion — With only $199.3 million in cash as of June 30, 2026, and high R&D spend (operating cash flow -$186.4M in 2025), the company may need to raise additional capital before reaching profitability.
• Competition in GA — Approved therapies for geographic atrophy exist (e.g., complement inhibitors from other companies), and vonaprument must show differentiated vision preservation to gain share.
• Manufacturing and commercial scale-up — As a development-stage company, Annexon has no commercial manufacturing or sales infrastructure; delays in building these capabilities could affect launch timelines.

Outlook

Management expects to report topline data from the ARCHER II Phase 3 trial of vonaprument in Q4 2026. The company plans to submit a BLA to the FDA for tanruprubart in GBS during Q4 2026, following positive open-label FORWARD study results. The EMA review of the tanruprubart MAA is ongoing. The company is also adding a Month 24 dual primary endpoint to the vonaprument program and launching an open-label extension study, extending the clinical program timeline.